Retatrutide Predicted Pricing 2026: $1,087-1,500 Projected List Price, $299-449 Self-Pay, FDA Filing in 2027

Retatrutide still has no price, and the FDA filing slipped to early 2027. Eli Lilly's retatrutide is a weekly injection that acts on three gut-hormone receptors: GLP-1, GIP, and glucagon. In the 80-week TRIUMPH-1 trial, the 12 mg dose cut body weight by 28.3%, about 70 pounds, and TRIUMPH-4, in people with knee osteoarthritis, showed 28.7% at 68 weeks. On July 23, 2026, Lilly reported two more wins, TRIUMPH-2 and TRIUMPH-3, and said it will submit a Biologics License Application (BLA), the formal FDA approval request, in the first quarter of 2027. Earlier guidance had pointed to late 2026, and Lilly told CNBC it needed more time on manufacturing data. A standard review takes about ten months, so a decision is likely in late 2027 or early 2028.

The price logic runs through Zepbound and Foundayo. Zepbound's list price, the wholesale acquisition cost (WAC), is $1,087 a month, and Lilly would need to price retatrutide above that to signal it is the stronger drug. But Lilly's own cash prices set a ceiling on what patients expect: Zepbound vials and KwikPen run $299 to $449 through LillyDirect, and Foundayo, Lilly's pill, runs $149 to $299. Under the November 2025 deal with the White House, Lilly promised most-favored-nation (MFN) pricing on every new medicine, which points to a Medicare price near $245, the figure set for Zepbound. Our working estimate is a list price of $1,087 to $1,500, self-pay of $299 to $449, and $25 with a commercial savings card.

Medicare coverage at launch is not guaranteed. The Medicare GLP-1 Bridge pays for obesity drugs with a $50 copay today, but only through December 31, 2027, a date CMS extended because the BALANCE Model will not launch in Medicare in 2027. If retatrutide arrives in 2028, Medicare's obesity coverage will depend on whatever replaces the Bridge, and that is the biggest open question in this forecast.

The gray market is growing faster than the regulators. Retatrutide exposures reported to America's Poison Centers averaged 95 a month in early 2026, up 265% from late 2025, and a CBS News investigation found more than 120 websites and more than 50 clinics selling it. Lilly filed six lawsuits against US sellers on August 12, 2026 and has flagged more than 14,000 listings worldwide. In Australia, the Therapeutic Goods Administration (TGA) named unapproved peptides, retatrutide included, a formal compliance priority in June 2026. Research-grade vials are labeled "not for human use," they are untested, and Lilly says they may contain the wrong dose or the wrong ingredient. Retatrutide is available legally only in Lilly's trials and, since August 3, 2026, through a narrow expanded-access program.

For the decision most readers face, see Should I Wait for Retatrutide?. For the compassionate-use story, see Compassionate Use and Obesity Drugs. For today's Lilly prices, see Zepbound Pricing: September 2026 and Foundayo Pricing: September 2026.